A retrospective, real-world study of systemic use of CDK 4/6 inhibitors in patients with ER positive (+) HER2 negative (-) metastatic breast cancer
Latest Information Update: 16 Jul 2021
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology